Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

514 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Gillessen S, et al. Among authors: de santis m, de bono js. Ann Oncol. 2015 Aug;26(8):1589-604. doi: 10.1093/annonc/mdv257. Epub 2015 Jun 3. Ann Oncol. 2015. PMID: 26041764 Free PMC article.
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.
Fizazi K, Tjulandin S, Salvioni R, Germà-Lluch JR, Bouzy J, Ragan D, Bokemeyer C, Gerl A, Fléchon A, de Bono JS, Stenning S, Horwich A, Pont J, Albers P, De Giorgi U, Bower M, Bulanov A, Pizzocaro G, Aparicio J, Nichols CR, Théodore C, Hartmann JT, Schmoll HJ, Kaye SB, Culine S, Droz JP, Mahé C. Fizazi K, et al. Among authors: de giorgi u, de bono js. J Clin Oncol. 2001 May 15;19(10):2647-57. doi: 10.1200/JCO.2001.19.10.2647. J Clin Oncol. 2001. PMID: 11352956
Reversing resistance to targeted therapy.
Vidal L, Attard G, Kaye S, De Bono J. Vidal L, et al. J Chemother. 2004 Nov;16 Suppl 4:7-12. doi: 10.1179/joc.2004.16.Supplement-1.7. J Chemother. 2004. PMID: 15688600 Review.
Making sense of antisense.
Vidal L, Blagden S, Attard G, de Bono J. Vidal L, et al. Eur J Cancer. 2005 Dec;41(18):2812-8. doi: 10.1016/j.ejca.2005.06.029. Epub 2005 Nov 9. Eur J Cancer. 2005. PMID: 16289851 Review.
Update on tubulin-binding agents.
Attard G, Greystoke A, Kaye S, De Bono J. Attard G, et al. Pathol Biol (Paris). 2006 Mar;54(2):72-84. doi: 10.1016/j.patbio.2005.03.003. Pathol Biol (Paris). 2006. PMID: 16545633 Review.
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours.
Greystoke A, Blagden S, Thomas AL, Scott E, Attard G, Molife R, Vidal L, Pacey S, Sarkar D, Jenner A, De-Bono JS, Steward W. Greystoke A, et al. Among authors: de bono js. Ann Oncol. 2006 Aug;17(8):1313-9. doi: 10.1093/annonc/mdl097. Epub 2006 May 25. Ann Oncol. 2006. PMID: 16728482 Free article. Clinical Trial.
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.
de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, Cockey L, Mason M, Graham J. de Bono JS, et al. J Clin Oncol. 2007 Jan 20;25(3):257-62. doi: 10.1200/JCO.2006.07.0888. J Clin Oncol. 2007. PMID: 17235043 Clinical Trial.
514 results